M&G Investment Management’s Pacira BioSciences PCRX Stock Holding History

M&G Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-145,170	Closed	-$5.95M	–	420
2023 Q1	$5.95M	Buy	+145,170	New	+$5.78M	0.03%	239
2021 Q3	–	Sell	-9,804	Closed	-$598	–	774
2021 Q2	$598	Buy	+9,804	New	+$621K	﹤0.01%	668

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

M&G Investment Management's PCRX Position: Q2 2023 in Review

M&G Investment Management sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 145,170 shares — an estimated $5.95M sold.

M&G Investment Management first reported a position in PCRX in Q2 2021 and held it in 2 quarters. The position peaked at $5.95M in Q1 2023. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

M&G Investment Management reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
M&G Investment Management sold 145,170 Pacira BioSciences shares in Q2 2023, an estimated $5.95M.
M&G Investment Management first reported a position in Pacira BioSciences in Q2 2021 and held it in 2 quarters.
M&G Investment Management's Pacira BioSciences position peaked at $5.95M in Q1 2023.
258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on M&G Investment Management's 13F filing for Q2 2023, filed 1 Aug 2023.